Pharmaxis Ltd., of Sydney, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, said Boehringer is starting the phase IIa ROBIN (Randomized study of Orally administered BI 1467335 in patients with Non-proliferative diabetic retinopathy without center-involved diabetic macular edema) trial testing BI-1467335 in 100 patients with moderately severe to severe nonproliferative diabetic retinopathy without center-involved diabetic macular edema.